<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ekso Bionics Holdings Inc — News on 6ix</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc</link>
<description>Latest news and press releases for Ekso Bionics Holdings Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 21 Jan 2026 13:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ekso-bionics-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835629a78dffbe2df0eee71.webp</url>
<title>Ekso Bionics Holdings Inc</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc</link>
</image>
<item>
<title>Ekso Bionics Prices $5.852 million Private Placement</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-prices-5-852-133000434</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-prices-5-852-133000434</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company’s Series B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase up to an agg</description>
</item>
<item>
<title>Applied Digital Reports Fiscal Second Quarter 2026 Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/applied-digital-reports-fiscal-second-quarter-2026-results</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/applied-digital-reports-fiscal-second-quarter-2026-results</guid>
<pubDate>Wed, 07 Jan 2026 21:48:00 GMT</pubDate>
<description>DALLAS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD) ("Applied Digital" or the "Company"), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking and blockchain workloads, reported financial results for the fiscal second quarter ended November 30, 2025. The Company also provided operational updates. Fiscal Second Quarter 2026 Continuing Operations Financial H</description>
</item>
<item>
<title>Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/applied-digital-to-spin-out-cloud-business-proposes-business-combination-with-ekso-to-launch-chronoscale</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/applied-digital-to-spin-out-cloud-business-proposes-business-combination-with-ekso-to-launch-chronoscale</guid>
<pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
<description>Proposed Business Combination with Nasdaq-listed EKSO to Form an Accelerated Focused GPU Platform Purpose Built for Next-Generation AI Workloads DALLAS, Dec.</description>
</item>
<item>
<title>Ekso Bionics Inks Agreement to Become the Exclusive U.S. Distributor of MediTouch’s Groundbreaking BalanceTutor™ Rehabilitation System</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-inks-agreement-become-124500221</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-inks-agreement-become-124500221</guid>
<pubDate>Thu, 04 Dec 2025 12:45:00 GMT</pubDate>
<description>SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States. The BalanceTutor is the only known</description>
</item>
<item>
<title>Ekso Bionics Announces $3.7 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-3-7-120000646</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-3-7-120000646</guid>
<pubDate>Wed, 29 Oct 2025 12:00:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on October 28, 2025, it entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 769,490 shares of the Company’s common stock at a purchase price of $4.81 per share of common stock in a registered direct offering priced at-the-market un</description>
</item>
<item>
<title>Ekso Bionics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-third-quarter-200500118</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-third-quarter-200500118</guid>
<pubDate>Tue, 28 Oct 2025 20:05:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and nine months ended September 30, 2025. Third Quarter 2025 Highlights and Accomplishments Revenue grew 2% year-over-year and rebounded 105% sequentially quarter-over-quarter to $4.2 millionGross margin increased 680 basis points year-over-yea</description>
</item>
<item>
<title>Ekso Bionics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-second-quarter-200500053</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-second-quarter-200500053</guid>
<pubDate>Mon, 28 Jul 2025 20:05:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into</description>
</item>
<item>
<title>Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-second-quarter-204500992</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-second-quarter-204500992</guid>
<pubDate>Mon, 21 Jul 2025 20:45:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To</description>
</item>
<item>
<title>Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/virtual-eksouniversity-support-continuing-education-120000089</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/virtual-eksouniversity-support-continuing-education-120000089</guid>
<pubDate>Fri, 18 Jul 2025 12:00:00 GMT</pubDate>
<description>On-demand courses already approved for CEUs in over 30 statesSAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists (“PTs”) and physical therapy assistants (“PTAs”) across the country. Most states require healthcare</description>
</item>
<item>
<title>Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-acceptance-nvidia-connect-113000029</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-acceptance-nvidia-connect-113000029</guid>
<pubDate>Wed, 18 Jun 2025 11:30:00 GMT</pubDate>
<description>AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successf</description>
</item>
<item>
<title>Ekso Bionics Announces New Effective Date of Reverse Stock Split</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-effective-date-203000876</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-effective-date-203000876</guid>
<pubDate>Wed, 21 May 2025 20:30:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for tr</description>
</item>
<item>
<title>Ekso Bionics Announces Reverse Stock Split</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-reverse-stock-203000410</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-announces-reverse-stock-203000410</guid>
<pubDate>Mon, 19 May 2025 20:30:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKS</description>
</item>
<item>
<title>Ekso Bionics Accepted into NVIDIA Connect Program</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-accepted-nvidia-connect-114500056</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-accepted-nvidia-connect-114500056</guid>
<pubDate>Thu, 15 May 2025 11:45:00 GMT</pubDate>
<description>Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, toda</description>
</item>
<item>
<title>Ekso Bionics Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-first-quarter-200500633</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-first-quarter-200500633</guid>
<pubDate>Mon, 05 May 2025 20:05:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility</description>
</item>
<item>
<title>Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-first-quarter-203000556</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-first-quarter-203000556</guid>
<pubDate>Mon, 28 Apr 2025 20:30:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To pa</description>
</item>
<item>
<title>Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/bionic-p-o-chosen-first-121600839</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/bionic-p-o-chosen-first-121600839</guid>
<pubDate>Wed, 23 Apr 2025 12:16:00 GMT</pubDate>
<description>Alliance marks Ekso Bionics’ first entrance into the O&P spaceSAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC (“Bionic P&O”), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor. Ekso Indego Personal is a we</description>
</item>
<item>
<title>Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-fourth-quarter-210500536</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-fourth-quarter-210500536</guid>
<pubDate>Mon, 03 Mar 2025 21:05:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating</description>
</item>
<item>
<title>Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-fourth-quarter-213000852</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-report-fourth-quarter-213000852</guid>
<pubDate>Mon, 24 Feb 2025 21:30:00 GMT</pubDate>
<description>SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business develo</description>
</item>
<item>
<title>NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/nsm-named-exclusive-distributor-of-ekso-indegor-personal-within-the-crt-industry</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/nsm-named-exclusive-distributor-of-ekso-indegor-personal-within-the-crt-industry</guid>
<pubDate>Mon, 10 Feb 2025 05:00:00 GMT</pubDate>
<description>Move expected to broaden access to Ekso Bionics’ portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges</description>
</item>
<item>
<title>Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results</title>
<link>https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-certain-preliminary-fourth-quarter-2024-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ekso-bionics-holdings-inc/news/ekso-bionics-reports-certain-preliminary-fourth-quarter-2024-financial-results</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>Expects Record Revenues for the Fourth Quarter of 2024 SAN RAFAEL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the</description>
</item>
</channel>
</rss>